<!DOCTYPE html PUBLIC '-//W3C//DTD XHTML 1.0 Transitional//EN' 'http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd'>
<html xmlns='http://www.w3.org/1999/xhtml'>
<head>
<meta http-equiv='Content-Type' content='text/html; charset=utf-8' />
<meta http-equiv='X-UA-Compatible' content='IE=edge' />
<meta name='viewport' content='width=device-width, initial-scale=1.0' />
<meta name='format-detection' content='telephone=no' />
<title></title>
<!--[if gte mso 15]>
<style type='text/css'>
	table { font-size:1px; line-height:0; mso-margin-top-alt:1px; }
</style>
<![endif]-->
<style type='text/css'>
	@media only screen and (min-device-width: 1px) and (max-device-width: 569px), only screen and (max-device-width: 640px) and (-webkit-min-device-pixel-ratio:.75), only screen and (max-device-width: 640px) and (-webkit-min-device-pixel-ratio: 1), only screen and (max-device-width: 640px) and (-webkit-min-device-pixel-ratio: 1.5), only screen and (min-device-width: 570px) and (max-device-width: 720px) and (orientation:portrait) {
		table[class=w320], td[class=w320] { width:320px !important; }
		table[class=w300], td[class=w300] { width:300px !important; }
		table[class=w284], td[class=w284] { width:284px !important; }
		table[class=w280], td[class=w280] { width:280px !important; }
		table[class=w10], td[class=w10] { width:10px !important; }
		table[class=w9], td[class=w9] { width:9px !important; }
		table[class=hide], tr[class=hide], td[class=hide], br[class=hide], img[class=hide], span[class=hide], div[class=hide], font[class=hide] { display:none !important; visibility:hidden; }
		font[class=block] { display:block !important; }
		img[class=w320] { width:320px !important; height:auto !important; }
		img[class=w300] { width:300px !important; height:auto !important; }
		img[class=w280] { width:280px !important; height:auto !important; }
		td[class=float320] { clear:both !important; float:left !important; width:320px !important; }
		td[class=float300] { clear:both !important; float:left !important; width:300px !important; }
		td[class=float280] { clear:both !important; float:left !important; width:280px !important; }
	}
	#outlook a { padding:0; }
	body{width:100% !important; margin:0; padding:0; background-color:#ffffff;}
	.ExternalClass { width:100% !important;	display:block !important; }
	.ExternalClass * { line-height:100%; }
	table, td {border-spacing:0; border-collapse: collapse; mso-table-lspace:0pt; mso-table-rspace:0pt; }
</style>
</head>

<body bgcolor='#ffffff' style='width:100% !important; margin:0; padding:0; background-color:#ffffff;'>
<table width='100%' cellpadding='0' cellspacing='0' border='0'>
	<tr>
    	<td align='center'><table width='600' cellpadding='0' cellspacing='0' border='0' class='w320'>
        	<tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none;'><td width='600' class='w320' height='19' bgcolor='#124a89'><font style='display:none;'>&nbsp;</font></td></tr>
            <tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none;'><td width='600' class='w320' height='19' bgcolor='#e4f1fa'><font style='display:none;'>&nbsp;</font></td></tr>
        	<tr>
            	<td width='600' bgcolor='#e4f1fa' class='w320' align='left'>
                    <table width='275' cellpadding='0' cellspacing='0' border='0' class='w320' align='right'>
                    	<tr>
                            <td width='246' class='w320' align='center'><table width='246' cellpadding='0' cellspacing='0' border='0'>
                            	<tr class='hide'><td width='246' height='26' class='hide'></td></tr>
                            	<tr>
                                	<td width='246'><img src='cid:tuss14cdpr1130_complera_logo.png' width='246' border='0' alt='COMPLEAR&reg; ~ emtricitabine 200mg/rilpivirine 25mg/tenofovir disoproxil fumarate 300mb tablets' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                </tr>
                                <tr><td width='246' height='30'></td></tr>
                            </table></td>
                            <td width='29' class='hide'></td>
                        </tr>
                    </table>
                	<table width='294' cellpadding='0' cellspacing='0' border='0' bgcolor='#124a89' class='w320'>
                        <tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none; mso-margin-top-alt:1px;'>
                            <td width='22' bgcolor='#124a89' class='w10'><font style='display:none;'>&nbsp;</font></td>
                            <td bgcolor='#124a89' class='w300'><font style='display:none;'>&nbsp;</font></td>
                            <td width='14' bgcolor='#124a89' class='w10' height='13'><img src='cid:tuss14cdpr1130_box1_corner_tr.gif' width='14' height='13' border='0' class='hide' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                        </tr>
                        <tr>
                            <td width='22' bgcolor='#124a89' class='w10'></td>
                            <td bgcolor='#124a89' class='w300'>
                            	<div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:18px; line-height:20px; color:#ffcb5d; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong style='color:#ffcb5d !important;'><span style='color:#ffcb5d !important;'>DHHS-RECOMMENDED</span></strong></div>
                                <div style='font-size:6px; line-height:8px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:13px; line-height:15px; color:#ffffff; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>in adults with no ARV treatment history with pretreatment HIV RNA &lt;100,000 copies/mL and with CD4 count &gt;200 cells/mm<sup style='vertical-align:super; font-size:80%; line-height:0.5em;'>3</sup>.<sup style='vertical-align:super; font-size:80%; line-height:0.5em;'>2</sup></div>
                            </td>
                            <td width='14' bgcolor='#124a89' class='w10'></td>
                        </tr>
                        <tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none; mso-margin-top-alt:1px;'>
                            <td width='22' bgcolor='#124a89' class='w10'><font style='display:none;'>&nbsp;</font></td>
                            <td bgcolor='#124a89' class='w300'><font style='display:none;'>&nbsp;</font></td>
                            <td width='14' bgcolor='#124a89' class='w10' height='13'><img src='cid:tuss14cdpr1130_box1_corner_br.gif' width='14' height='13' border='0' class='hide' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                        </tr>
                    </table>
                </td>
            </tr>
            <tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none;'><td width='600' class='w320' height='30' bgcolor='#e4f1fa'><font style='display:none;'>&nbsp;</font></td></tr>
            <tr>
            	<td width='600' bgcolor='#e4f1fa' class='w320'><table width='600' cellpadding='0' cellspacing='0' border='0' class='w320'>
                	<tr>
                    	<td width='35' class='w10'></td>
                        <td width='545' class='w300'>
                        	<div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>Dear Healthcare Provider:</div>
                            <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>This email provides information on replacing current antiretroviral therapy in certain stably suppressed adults with no history of virologic failure and no resistance to COMPLERA.</div>
                            <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>COMPLERA is indicated as a complete regimen for the treatment of HIV-1 infection in certain virologically suppressed (HIV-1 RNA &lt;50 copies/mL) adults on a stable ARV regimen at the start of therapy to replace their current regimen; efficacy was established in patients who were virologically suppressed on a stable protease inhibitor and ritonavir-containing regimen. Additional monitoring of HIV-1 RNA and regimen tolerability is recommended after replacing therapy to assess for potential virologic failure or rebound. COMPLERA is not recommended for patients &lt;18 years of&nbsp;age.</div>
                            <div style='font-size:8px; line-height:10px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <table width='545' cellpadding='0' cellspacing='0' border='0' class='w300'>
                            	<tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Prescribing considerations in virologically suppressed adults:</strong> Patients must:</div></td>
                                </tr>
                            </table>
                            <div style='font-size:8px; line-height:10px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <table width='545' cellpadding='0' cellspacing='0' border='0' class='w300'>
                            	<tr>
                                	<td width='18'></td>
                                    <td width='13' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>&ndash;</div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>Have no history of virologic failure</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                	<td width='18'></td>
                                    <td width='13' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>&ndash;</div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>Be stably suppressed (HIV-1 RNA &lt;50 copies/mL) for &ge;6 months prior to switching&nbsp;therapy</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                	<td width='18'></td>
                                    <td width='13' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>&ndash;</div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>Currently be on their first or second ARV regimen prior to switching therapy</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                	<td width='18'></td>
                                    <td width='13' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>&ndash;</div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>Have no current history of resistance to any component of COMPLERA</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                            </table>
                            <div style='font-size:14px; line-height:18px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>IMPORTANT SAFETY INFORMATION</strong></div>
                            <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>BOXED WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS&nbsp;B</strong></div>
                            <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <table width='545' cellpadding='0' cellspacing='0' border='0' class='w300'>
                            	<tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate (tenofovir DF), a component of COMPLERA, in combination with other antiretrovirals</strong></div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>COMPLERA is not approved for the treatment of chronic hepatitis B virus (HBV) infection and the safety and efficacy of COMPLERA have not been established in patients coinfected with HBV and HIV-1. Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HBV and HIV-1 and have discontinued emtricitabine or tenofovir DF, which are components of COMPLERA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue COMPLERA. If appropriate, initiation of anti-hepatitis B therapy may be warranted</strong></div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                            </table>
                             <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Please see additional Important Safety Information below and full <a href='#tbd' target='_blank' style='color:#124a89; text-decoration:underline;'>Prescribing Information</a>, including BOXED WARNING.</strong></div>
                             <div style='font-size:14px; line-height:18px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                             <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>SPIRIT Study Design<sup style='vertical-align:super; font-size:80%; line-height:0.5em;'>3,4</sup></strong></div>
                          <div style='font-size:5px; line-height:8px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                        </td>
                        <td width='20' class='w10'></td>
                    </tr>
                </table></td>
            </tr>
            <tr>
            	<td width='600' bgcolor='#e4f1fa' class='w320'><table width='600' cellpadding='0' cellspacing='0' border='0' class='w320'>
                	<tr>
                    	<td width='25' class='w10'></td>
                        <td width='555' class='w300'>
                             <table width='555' cellpadding='0' cellspacing='0' border='0' class='w300'>
                             	<tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none; mso-margin-top-alt:1px;'>
                                	<td width='8' bgcolor='#ffffff'><img src='cid:tuss14cdpr1130_box2_corner_tl.gif' width='8' height='8' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                    <td width='539' class='w284' valign='top' bgcolor='#ffffff'><table width='539' class='w284' cellpadding='0' cellspacing='0' border='0'>
                                    	<tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none;'><td width='539' class='w284' height='1' bgcolor='#75aede'><font style='display:none;'>&nbsp;</font></td></tr>
                                    </table></td>
                                    <td width='8' bgcolor='#ffffff'><img src='cid:tuss14cdpr1130_box2_corner_tr.gif' width='8' height='8' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                </tr>
                             </table>
                             <table width='555' cellpadding='0' cellspacing='0' border='0' class='w300'>
                             	<tr>
                                	<td width='1' bgcolor='#75aede'></td>
                                    <td width='16' bgcolor='#ffffff' class='w9'></td>
                                  	<td width='521' bgcolor='#ffffff' class='w280' align='center'>
                                    	<div style='font-size:5px; line-height:8px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                    	<div align='center' style='font-family:Arial, Helvetica, sans-serif; font-size:15px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Study design</strong></div>
                                        <div style='font-size:13px; line-height:16px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                      	<table width='521' class='w280' cellpadding='0' cellspacing='0' border='0'>
                                        	<tr>
                                            	<td width='26' class='hide'></td>
                                            	<td width='485' class='w280'><img src='cid:tuss14cdpr1130_diagram1.gif' width='485' height='175' border='0' alt='DIAGRAM :: Start of study | 24 weeks | 48 weeks' class='w280' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                                <td width='10' class='hide'></td>
                                            </tr>
                                        </table>
                                        <div style='font-size:13px; line-height:16px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                        <table width='521' cellpadding='0' cellspacing='0' border='0' class='w280'>
                                        	<tr>
                                            	<td width='26' class='hide'></td>
                                                <td width='495' class='w280'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:12px; line-height:16px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>SPIRIT was a 48-week, phase 3b, prospective, randomized, open-label study<br class='hide' /> in certain stably suppressed (HIV-1 RNA &lt;50 copies/mL) subjects.</strong></div></td>
                                            </tr>
                                        </table>
                                        <div style='font-size:10px; line-height:12px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                        <table width='521' cellpadding='0' cellspacing='0' border='0' class='w280'>
                                        	<tr>
                                                <td width='1' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:9px; line-height:11px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><sup style='vertical-align:super; font-size:80%; line-height:0.5em;'>a</sup></div></td>
                                                <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:9px; line-height:11px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>20 subjects discontinued before Week 24 (adverse event, n=7; withdrew consent, n=4; lost to follow-up, n=4; protocol violation, n=3; lack of efficacy, n=1; investigator discretion, n=1). 7 subjects discontinued before Week 48 (withdrew consent, n=2; lost to follow-up, n=2; lack of efficacy, n=1; subject noncompliance, n=1; protocol violation, n=1).</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                            </tr>
                                            <tr>
                                                <td width='1' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:9px; line-height:11px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><sup style='vertical-align:super; font-size:80%; line-height:0.5em;'>b</sup></div></td>
                                                <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:9px; line-height:11px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>95% of subjects received 3 pills. 7 subjects discontinued before switching to COMPLERA (withdrew consent, n=3; investigator discretion, n=1; lost to follow-up, n=1; subject noncompliance, n=1; protocol violation, n=1).</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                            </tr>
                                            <tr>
                                                <td width='1' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:9px; line-height:11px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><sup style='vertical-align:super; font-size:80%; line-height:0.5em;'>c</sup></div></td>
                                                <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:9px; line-height:11px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>152 subjects switched to COMPLERA at Week 24. 9 subjects discontinued after switching to COMPLERA (adverse event, n=5; withdrew consent, n=2; lack of efficacy, n=1; protocol violation, n=1).</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                            </tr>
                                            <tr>
                                                <td width='1' align='left' valign='top'></td>
                                                <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:9px; line-height:11px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>NRTI=nucleoside reverse transcriptase inhibitor; PI=protease inhibitor; RTV=ritonavir.</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                            </tr>
                                            <tr>
                                                <td width='1' align='left' valign='top'></td>
                                                <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:9px; line-height:11px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>Pills shown are not actual size.</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                            </tr>
                                        </table>
                                    </td>
                                    <td width='16' bgcolor='#ffffff' class='w9'></td>
                                    <td width='1' bgcolor='#75aede'></td>
                                </tr>
                             </table>
                             <table width='555' cellpadding='0' cellspacing='0' border='0' class='w300'>
                             	<tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none; mso-margin-top-alt:1px;'>
                                	<td width='8' bgcolor='#ffffff'><img src='cid:tuss14cdpr1130_box2_corner_bl.gif' width='8' height='8' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                    <td width='539' class='w284' valign='bottom' bgcolor='#ffffff'><table width='539' class='w284' cellpadding='0' cellspacing='0' border='0'>
                                    	<tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none;'><td width='539' class='w284' height='1' bgcolor='#75aede'><font style='display:none;'>&nbsp;</font></td></tr>
                                    </table></td>
                                    <td width='8' bgcolor='#ffffff'><img src='cid:tuss14cdpr1130_box2_corner_br.gif' width='8' height='8' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                </tr>
                             </table>
                        </td>
                        <td width='20' class='w10'></td>
                    </tr>
                </table></td>
            </tr>
        </table></td>
    </tr>
</table>
<table width='100%' cellpadding='0' cellspacing='0' border='0'>
	<tr>
    	<td align='center'><table width='600' cellpadding='0' cellspacing='0' border='0' class='w320'>
            <tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none;'><td width='600' class='w320' height='21' bgcolor='#e4f1fa'><font style='display:none;'>&nbsp;</font></td></tr>
            <tr>
            	<td width='600' bgcolor='#e4f1fa' class='w320' align='left'><table width='600' cellpadding='0' cellspacing='0' border='0' class='w320'>
                	<tr>
                    	<td width='35' class='w10'></td>
                        <td width='545' class='w300'>
                        	<div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Objective:</strong> Evaluate the efficacy and safety of switching from a PI + RTV + 2 NRTIs to COMPLERA in certain stably suppressed HIV-1 infected adults.</div>
                            <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                          <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Primary endpoint:</strong> Noninferior viral suppression (HIV-1 RNA &lt;50 copies/mL) when switching to COMPLERA vs remaining on a PI-based regimen at 24 weeks.</div>
                            <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Secondary endpoints:</strong> Changes in serum lipid levels, change in CD4 cell count, and safety and tolerability at 24 and 48 weeks; efficacy (HIV-1 RNA &lt;50 copies/mL) at 48 weeks.</div>
                            <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Inclusion criteria:</strong></div>
                            <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <table width='545' cellpadding='0' cellspacing='0' border='0' class='w300'>
                            	<tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>Subjects were on their first or second ARV regimen with no history of virologic failure</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>Subjects had no NNRTI experience</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>No current or history of resistance to any of the components of COMPLERA</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>Suppressed (HIV-1 RNA &lt;50 copies/mL) for at least 6 months before screening</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>No exclusion criteria based on subject's viral load before any ARV treatment</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                            </table>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Dosing:</strong> COMPLERA was dosed once daily with a meal at the same time each day.<br class='hide' /> PI + RTV + 2 NRTIs were administered according to manufacturers&rsquo; labels.</div>
                            <div style='font-size:14px; line-height:18px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>COMPLERA Maintained Viral Suppression at Week 48<sup style='vertical-align:super; font-size:80%; line-height:0.5em;'>3,4</sup></strong></div>
                             <div style='font-size:5px; line-height:8px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                       </td>
                       <td width='20' class='w10'></td>
                   </tr>
               </table></td>
            </tr>
        	<tr>
            	<td width='600' bgcolor='#e4f1fa' class='w320' align='left'><table width='600' cellpadding='0' cellspacing='0' border='0' class='w320'>
                	<tr>
                    	<td width='25' class='w10'></td>
                        <td width='555' class='w300'>
                             <table width='555' cellpadding='0' cellspacing='0' border='0' class='w300'>
                             	<tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none; mso-margin-top-alt:1px;'>
                                	<td width='8' bgcolor='#ffffff'><img src='cid:tuss14cdpr1130_box2_corner_tl.gif' width='8' height='8' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                    <td width='539' class='w284' valign='top' bgcolor='#ffffff'><table width='539' class='w284' cellpadding='0' cellspacing='0' border='0'>
                                    	<tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none;'><td width='539' class='w284' height='1' bgcolor='#75aede'><font style='display:none;'>&nbsp;</font></td></tr>
                                    </table></td>
                                    <td width='8' bgcolor='#ffffff'><img src='cid:tuss14cdpr1130_box2_corner_tr.gif' width='8' height='8' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                </tr>
                             </table>
                             <table width='555' cellpadding='0' cellspacing='0' border='0' class='w300'>
                             	<tr>
                                	<td width='1' bgcolor='#75aede'></td>
                                    <td width='16' bgcolor='#ffffff' class='w9'></td>
                                  	<td width='521' bgcolor='#ffffff' class='w280' align='center'>
                                    	<div style='font-size:5px; line-height:8px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                    	<div align='center' style='font-family:Arial, Helvetica, sans-serif; font-size:15px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Virologic Outcomes</strong></div>
                                        <div style='font-size:13px; line-height:16px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                      	<table width='521' class='w280' cellpadding='0' cellspacing='0' border='0'>
                                        	<tr>
                                            	<td width='518' class='w280'><img src='cid:tuss14cdpr1130_diagram2.gif' alt='DIAGRAM :: Virologic Success | Virologic Failure' width='518' height='287' border='0' class='w280' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                              <td width='3' class='hide'></td>
                                            </tr>
                                        </table>
                                        <div style='font-size:13px; line-height:16px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                        <table width='521' cellpadding='0' cellspacing='0' border='0' class='w280'>
                                        	<tr>
                                                <td width='1' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:9px; line-height:11px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><sup style='vertical-align:super; font-size:80%; line-height:0.5em;'>a</sup></div></td>
                                                <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:9px; line-height:11px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>HIV-1 RNA &lt;50 copies/mL.</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                            </tr>
                                            <tr>
                                                <td width='1' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:9px; line-height:11px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><sup style='vertical-align:super; font-size:80%; line-height:0.5em;'>b</sup></div></td>
                                                <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:9px; line-height:11px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>HIV-1 RNA &ge;50 copies/mL. Includes subjects who had HIV-1 RNA &ge;50 copies/mL in the time window, subjects who discontinued early due to lack or loss of efficacy, and subjects who discontinued for reasons other than an adverse event or death and at the time of discontinuation had a viral load value of &ge;50 copies/mL.</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                            </tr>
                                        </table>
                                    </td>
                                    <td width='16' bgcolor='#ffffff' class='w9'></td>
                                    <td width='1' bgcolor='#75aede'></td>
                                </tr>
                             </table>
                             <table width='555' cellpadding='0' cellspacing='0' border='0' class='w300'>
                             	<tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none; mso-margin-top-alt:1px;'>
                                	<td width='8' bgcolor='#ffffff'><img src='cid:tuss14cdpr1130_box2_corner_bl.gif' width='8' height='8' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                    <td width='539' class='w284' valign='bottom' bgcolor='#ffffff'><table width='539' class='w284' cellpadding='0' cellspacing='0' border='0'>
                                    	<tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none;'><td width='539' class='w284' height='1' bgcolor='#75aede'><font style='display:none;'>&nbsp;</font></td></tr>
                                    </table></td>
                                    <td width='8' bgcolor='#ffffff'><img src='cid:tuss14cdpr1130_box2_corner_br.gif' width='8' height='8' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                </tr>
                             </table>
                       </td>
                       <td width='20' class='w10'></td>
                   </tr>
               </table></td>
            </tr>
        </table></td>
    </tr>
</table>
<table width='100%' cellpadding='0' cellspacing='0' border='0'>
	<tr>
    	<td align='center'><table width='600' cellpadding='0' cellspacing='0' border='0' class='w320'>
            <tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none;'><td width='600' class='w320' height='12' bgcolor='#e4f1fa'><font style='display:none;'>&nbsp;</font></td></tr>
            <tr>
            	<td width='600' bgcolor='#e4f1fa' class='w320' align='left'><table width='600' cellpadding='0' cellspacing='0' border='0' class='w320'>
                	<tr>
                    	<td width='35' class='w10'></td>
                        <td width='545' class='w300'>
                        	<div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>IMPORTANT SAFETY INFORMATION</strong></div>
                            <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                          <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Contraindications</strong></div>
                            <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <table width='545' cellpadding='0' cellspacing='0' border='0' class='w300'>
                            	<tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Coadministration:</strong> COMPLERA should not be coadministered with drugs that induce CYP3A or increase gastric pH as this may lead to loss of virologic response and possible resistance to COMPLERA or the NNRTI class. Use of the following drugs with COMPLERA is contraindicated: carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, proton pump inhibitors (e.g., esomeprazole, lansoprazole, dexlansoprazole, omeprazole, pantoprazole, rabeprazole), systemic dexamethasone (&gt;1 dose) and St. John&rsquo;s wort</div></td>
                                </tr>
                            </table>
                            <div style='font-size:14px; line-height:18px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Resistance Profile in SPIRIT<sup style='vertical-align:super; font-size:80%; line-height:0.5em;'>3,4</sup></strong></div>
                             <div style='font-size:5px; line-height:8px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                       </td>
                       <td width='20' class='w10'></td>
                   </tr>
               </table></td>
            </tr>
        	<tr>
            	<td width='600' bgcolor='#e4f1fa' class='w320' align='left'><table width='600' cellpadding='0' cellspacing='0' border='0' class='w320'>
                	<tr>
                    	<td width='25' class='w10'></td>
                        <td width='555' class='w300'>
                             <table width='555' cellpadding='0' cellspacing='0' border='0' class='w300'>
                             	<tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none; mso-margin-top-alt:1px;'>
                                	<td width='8' bgcolor='#ffffff'><img src='cid:tuss14cdpr1130_box2_corner_tl.gif' width='8' height='8' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                    <td width='539' class='w284' valign='top' bgcolor='#ffffff'><table width='539' class='w284' cellpadding='0' cellspacing='0' border='0'>
                                    	<tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none;'><td width='539' class='w284' height='1' bgcolor='#75aede'><font style='display:none;'>&nbsp;</font></td></tr>
                                    </table></td>
                                    <td width='8' bgcolor='#ffffff'><img src='cid:tuss14cdpr1130_box2_corner_tr.gif' width='8' height='8' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                </tr>
                             </table>
                             <table width='555' cellpadding='0' cellspacing='0' border='0' class='w300'>
                             	<tr>
                                	<td width='1' bgcolor='#75aede'></td>
                                    <td width='16' bgcolor='#ffffff' class='w9'></td>
                                  	<td width='521' bgcolor='#ffffff' class='w280' align='center'>
                                    	<div style='font-size:5px; line-height:8px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                    	<div align='center' style='font-family:Arial, Helvetica, sans-serif; font-size:15px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Resistance developed in &lt;1% of subjects who switched<br class='hide' /> to COMPLERA (0.9%; 4/469) through 48 weeks or stayed on their<br class='hide' /> PI-based regimen (0.6%; 1/159) through 24 weeks</strong></div>
                                        <div style='font-size:13px; line-height:16px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                      	<table width='521' class='w280' cellpadding='0' cellspacing='0' border='0'>
                                        	<tr>
                                            	<td width='12' class='hide'></td>
                                                <td width='230' class='float280' valign='top' align='left'>
                                                	<table width='230' cellpadding='0' cellspacing='0' border='0' class='w280'>
                                                    	<tr>
                                                        	<td width='40' valign='middle'><div align='center' style='font-family:Arial, Helvetica, sans-serif; font-size:25px; line-height:27px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>469</strong></div></td>
                                                            <td width='10'></td>
                                                            <td valign='middle'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>subjects switched to COMPLERA at start of study or at Week 24</div></td>
                                                        </tr>
                                                    </table>
                                                    <div style='font-size:2px; line-height:3px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                                    <table width='230' cellpadding='0' cellspacing='0' border='0' class='w280'>
                                                    	<tr>
                                                       	    <td width='40' valign='middle' align='center'><table width='12' cellpadding='0' cellspacing='0' border='0'>
                                                            	<tr>
                                                                	<td width='12'><img src='cid:tuss14cdpr1130_downarrow.gif' width='12' height='15' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                                                </tr>
                                                            </table></td>
                                                            <td></td>
                                                        </tr>
                                                    </table>
                                                    <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                                    <table width='230' cellpadding='0' cellspacing='0' border='0' class='w280'>
                                                    	<tr>
                                                        	<td width='40' valign='middle'><div align='center' style='font-family:Arial, Helvetica, sans-serif; font-size:25px; line-height:27px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>7</strong></div></td>
                                                            <td width='10'></td>
                                                            <td valign='middle'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>subjects were viremic and analyzed for resistance mutations</div></td>
                                                        </tr>
                                                    </table>
                                                    <div style='font-size:2px; line-height:3px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                                    <table width='230' cellpadding='0' cellspacing='0' border='0' class='w280'>
                                                    	<tr>
                                                       	    <td width='40' valign='middle' align='center'><table width='12' cellpadding='0' cellspacing='0' border='0'>
                                                            	<tr>
                                                                	<td width='12'><img src='cid:tuss14cdpr1130_downarrow.gif' width='12' height='15' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                                                </tr>
                                                            </table></td>
                                                            <td></td>
                                                        </tr>
                                                    </table>
                                                    <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                                    <table width='230' cellpadding='0' cellspacing='0' border='0' class='w280'>
                                                    	<tr>
                                                        	<td width='40' valign='middle'><div align='center' style='font-family:Arial, Helvetica, sans-serif; font-size:25px; line-height:27px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>4</strong></div></td>
                                                            <td width='10'></td>
                                                            <td valign='middle'>
                                                            	<div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>subjects had 1 or more resistance mutations<sup style='vertical-align:super; font-size:80%; line-height:0.5em;'>a</sup></div></td>
                                                        </tr>
                                                        <tr>
                                                        	<td width='40'></td>
                                                            <td width='10'></td>
                                                            <td>
                                                            	<div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                                            	<table cellpadding='0' cellspacing='0' border='0'>
                                                                    <tr>
                                                                        <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                                                        <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>M184V/I</div><div style='font-size:2px; line-height:3px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                                                    </tr>
                                                                    <tr>
                                                                        <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                                                        <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>M184V/I, E138E/K</div><div style='font-size:2px; line-height:3px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                                                    </tr>
                                                                    <tr>
                                                                        <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                                                        <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>M184V/I, K103N + L100I with<br class='hide' /> pre-existing V90V/Ib</div><div style='font-size:2px; line-height:3px;; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                                                    </tr>
                                                                    <tr>
                                                                        <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                                                        <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>M184V/I, E138K + V108V/I with<br class='hide' /> pre-existing K103N and V179V/I</div><div style='font-size:13px; line-height:16px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                                                    </tr>
                                                                </table>
                                                            </td>
                                                        </tr>
                                                    </table>
                                                </td>
                                                <td width='10' class='hide'></td>
                                                <td width='1' bgcolor='#6da6d7' class='hide'></td>
                                                <td width='15' class='hide'></td>
                                            	<td width='240' class='float280' valign='top' align='left'>
                                            	 	<table width='240' class='w280' cellpadding='0' cellspacing='0' border='0'>
                                                        <tr>
                                                          <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                                          <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>Of the 159 subjects that stayed on a PI-based regimen for 24 weeks, 1 subject (0.6%) developed NRTI resistance (M184V and K70K/E). This subject was also resistant to lamivudine</div>
                                                              <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                                        </tr>
                                                        <tr>
                                                          <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                                          <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>92% (22/24) of subjects with pre-existing K103N mutations who switched to COMPLERA maintained virologic suppression at Week 48</div>
                                                              <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                                        </tr>
                                                  	</table>
                                                    <table width='240' cellpadding='0' cellspacing='0' border='0' class='w280'>
                                                        <tr>
                                                            <td width='18'></td>
                                                            <td width='13' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>&ndash;</div></td>
                                                            <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>1 subject had pre-existing K103N and V179V/I and experienced virologic failure and 1 other subject had no data in the window</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                                        </tr>
                                                        <tr>
                                                            <td width='18'></td>
                                                            <td width='13' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>&ndash;</div></td>
                                                            <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>The K103N substitution alone does not show reduced susceptibility to rilpivirine in in vitro analyses; however, the combination of K103N and L100I resulted in a 7-fold reduced susceptibility to rilpivirine</div></td>
                                                        </tr>
                                                    </table>
                                                </td>
                                                <td width='13' class='hide'></td>
                                            </tr>
                                        </table>
                                        <div style='font-size:13px; line-height:16px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                        <table width='521' cellpadding='0' cellspacing='0' border='0' class='w280'>
                                        	<tr>
                                                <td width='1' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:9px; line-height:11px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><sup style='vertical-align:super; font-size:80%; line-height:0.5em;'>a</sup></div></td>
                                                <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:9px; line-height:11px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>These 4 subjects lost susceptibility to emtricitabine and were also resistant to lamivudine; 3 lost susceptibility to rilpivirine based on genotypic resistance. The 2 subjects with phenotypic resistance to rilpivirine developed cross-resistance to efavirenz and nevirapine, but 1 remained susceptible to etravirine. All subjects remained susceptible to tenofovir.</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                            </tr>
                                            <tr>
                                                <td width='1' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:9px; line-height:11px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><sup style='vertical-align:super; font-size:80%; line-height:0.5em;'>b</sup></div></td>
                                                <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:9px; line-height:11px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>Protocol violator with history of efavirenz use and baseline HIV-1 RNA &lt;1000 copies/mL. This subject never became virologically suppressed and developed additional resistance mutations by Week 4.</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                            </tr>
                                        </table>
                                    </td>
                                    <td width='16' bgcolor='#ffffff' class='w9'></td>
                                    <td width='1' bgcolor='#75aede'></td>
                                </tr>
                             </table>
                             <table width='555' cellpadding='0' cellspacing='0' border='0' class='w300'>
                             	<tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none; mso-margin-top-alt:1px;'>
                                	<td width='8' bgcolor='#ffffff'><img src='cid:tuss14cdpr1130_box2_corner_bl.gif' width='8' height='8' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                    <td width='539' class='w284' valign='bottom' bgcolor='#ffffff'><table width='539' class='w284' cellpadding='0' cellspacing='0' border='0'>
                                    	<tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none;'><td width='539' class='w284' height='1' bgcolor='#75aede'><font style='display:none;'>&nbsp;</font></td></tr>
                                    </table></td>
                                    <td width='8' bgcolor='#ffffff'><img src='cid:tuss14cdpr1130_box2_corner_br.gif' width='8' height='8' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                </tr>
                             </table>
                       </td>
                       <td width='20' class='w10'></td>
                   </tr>
               </table></td>
            </tr>
        </table></td>
    </tr>
</table>
<table width='100%' cellpadding='0' cellspacing='0' border='0'>
	<tr>
    	<td align='center'><table width='600' cellpadding='0' cellspacing='0' border='0' class='w320'>
            <tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none;'><td width='600' class='w320' height='12' bgcolor='#e4f1fa'><font style='display:none;'>&nbsp;</font></td></tr>
            <tr>
            	<td width='600' bgcolor='#e4f1fa' class='w320' align='left'><table width='600' cellpadding='0' cellspacing='0' border='0' class='w320'>
                	<tr>
                    	<td width='35' class='w10'></td>
                        <td width='545' class='w300'>
                        	<div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Proven Safety and Tolerability Profile<sup style='vertical-align:super; font-size:80%; line-height:0.5em;'>4</sup></strong></div>
                            <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <table width='545' cellpadding='0' cellspacing='0' border='0' class='w300'>
                            	<tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>In combined phase 3 clinical trials (ECHO/THRIVE [n=550]), common Grade 2-4 adverse reactions reported were depressive disorders (2%), insomnia (2%), and headache (2%)</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>In this switch study (SPIRIT), no new types of adverse reactions to COMPLERA were identified in stably suppressed subjects switching to COMPLERA from a PI-based regimen; however, the frequency of adverse reactions increased by 20%</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                            </table>
                            <table width='545' cellpadding='0' cellspacing='0' border='0' class='w300'>
                            	<tr>
                                	<td width='18'></td>
                                    <td width='13' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>&ndash;</div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>Through Week 48, of subjects in the immediate switch arm with adverse reactions assessed to be related to COMPLERA, 61% (48/79) experienced adverse reactions that were Grade 1 in severity. The most common Grades 1-4, treatment-related adverse reactions occurring in 2% or more of subjects were fatigue (3.5%), diarrhea (3.2%), nausea (2.2%), and insomnia (2.2%).</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                	<td width='18'></td>
                                    <td width='13' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>&ndash;</div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>Through Week 48, 2% (7/317) of subjects in the immediate switch arm discontinued due to an adverse reaction</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                            </table>
                            <div style='font-size:14px; line-height:18px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>IMPORTANT SAFETY INFORMATION</strong></div>
                            <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Warnings and Precautions</strong></div>
                            <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <table width='545' cellpadding='0' cellspacing='0' border='0' class='w300'>
                            	<tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>New onset or worsening renal impairment:</strong> Cases of acute renal failure and Fanconi syndrome have been reported with the use of tenofovir DF. In all patients, assess estimated creatinine clearance (CrCl) prior to initiating and during therapy. In patients at risk for renal dysfunction, additionally monitor serum phosphorus, urine glucose, and urine protein. Do not administer COMPLERA in patients with CrCl &lt;50 mL/min. Avoid concurrent or recent use with a nephrotoxic agent. Cases of acute renal failure, some requiring hospitalization and renal replacement therapy, have been reported after initiation of high dose or multiple NSAIDs in patients with risk factors for renal dysfunction; consider alternatives to NSAIDs in these patients. Persistent or worsening bone pain, pain in extremities, fractures and/or muscular pain or weakness may be manifestations of proximal renal tubulopathy and should prompt an evaluation of renal function</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                            </table>
                            <div style='font-size:14px; line-height:18px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Serum Lipids in Patients Who Switched From a PI-based Regimen to COMPLERA<sup style='vertical-align:super; font-size:80%; line-height:0.5em;'>3,4</sup></strong></div>
                            <div style='font-size:5px; line-height:8px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                       </td>
                       <td width='20' class='w10'></td>
                   </tr>
               </table></td>
            </tr>
        	<tr>
            	<td width='600' bgcolor='#e4f1fa' class='w320' align='left'><table width='600' cellpadding='0' cellspacing='0' border='0' class='w320'>
                	<tr>
                    	<td width='25' class='w10'></td>
                        <td width='555' class='w300'>
                             <table width='555' cellpadding='0' cellspacing='0' border='0' class='w300'>
                             	<tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none; mso-margin-top-alt:1px;'>
                                	<td width='8' bgcolor='#ffffff'><img src='cid:tuss14cdpr1130_box2_corner_tl.gif' width='8' height='8' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                    <td width='539' class='w284' valign='top' bgcolor='#ffffff'><table width='539' class='w284' cellpadding='0' cellspacing='0' border='0'>
                                    	<tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none;'><td width='539' class='w284' height='1' bgcolor='#75aede'><font style='display:none;'>&nbsp;</font></td></tr>
                                    </table></td>
                                    <td width='8' bgcolor='#ffffff'><img src='cid:tuss14cdpr1130_box2_corner_tr.gif' width='8' height='8' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                </tr>
                             </table>
                             <table width='555' cellpadding='0' cellspacing='0' border='0' class='w300'>
                             	<tr>
                                	<td width='1' bgcolor='#75aede'></td>
                                    <td width='16' bgcolor='#ffffff' class='w9'></td>
                                  	<td width='521' bgcolor='#ffffff' class='w280' align='center'>
                                    	<div style='font-size:5px; line-height:8px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                    	<div align='center' style='font-family:Arial, Helvetica, sans-serif; font-size:15px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Mean fasting lipid levels in the immediate switch arm<br class='hide' /> at start of study, 24 weeks, and 48 weeks<sup style='vertical-align:super; font-size:80%; line-height:0.5em;'>a</sup></strong></div>
                                        <div style='font-size:13px; line-height:16px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                      	<table width='521' class='w280' cellpadding='0' cellspacing='0' border='0'>
                                        	<tr>
                                            	<td width='499' class='w280'><img src='cid:tuss14cdpr1130_diagram3.gif' alt='DIAGRAM :: Total Cholesterol | LDL Cholesterol | HDL Cholesterol | Triglycerides' width='499' height='207' border='0' class='w280' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                              <td width='22' class='hide'></td>
                                            </tr>
                                        </table>
                                        <div style='font-size:13px; line-height:16px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                        <table width='521' cellpadding='0' cellspacing='0' border='0' class='w280'>
                                        	<tr>
                                                <td width='1' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:9px; line-height:11px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><sup style='vertical-align:super; font-size:80%; line-height:0.5em;'>a</sup></div></td>
                                                <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:9px; line-height:11px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>Subjects taking lipid-modifying agents were included in the lipid analysis.</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                            </tr>
                                        </table>
                                    </td>
                                    <td width='16' bgcolor='#ffffff' class='w9'></td>
                                    <td width='1' bgcolor='#75aede'></td>
                                </tr>
                             </table>
                             <table width='555' cellpadding='0' cellspacing='0' border='0' class='w300'>
                             	<tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none; mso-margin-top-alt:1px;'>
                                	<td width='8' bgcolor='#ffffff'><img src='cid:tuss14cdpr1130_box2_corner_bl.gif' width='8' height='8' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                    <td width='539' class='w284' valign='bottom' bgcolor='#ffffff'><table width='539' class='w284' cellpadding='0' cellspacing='0' border='0'>
                                    	<tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none;'><td width='539' class='w284' height='1' bgcolor='#75aede'><font style='display:none;'>&nbsp;</font></td></tr>
                                    </table></td>
                                    <td width='8' bgcolor='#ffffff'><img src='cid:tuss14cdpr1130_box2_corner_br.gif' width='8' height='8' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                </tr>
                             </table>
                       </td>
                       <td width='20' class='w10'></td>
                   </tr>
               </table></td>
            </tr>
        </table></td>
    </tr>
</table>
<table width='100%' cellpadding='0' cellspacing='0' border='0'>
	<tr>
    	<td align='center'><table width='600' cellpadding='0' cellspacing='0' border='0' class='w320'>
            <tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none;'><td width='600' class='w320' height='12' bgcolor='#e4f1fa'><font style='display:none;'>&nbsp;</font></td></tr>
            <tr>
            	<td width='600' bgcolor='#e4f1fa' class='w320' align='left'><table width='600' cellpadding='0' cellspacing='0' border='0' class='w320'>
                	<tr>
                    	<td width='35' class='w10'></td>
                        <td width='545' class='w300'>
                        	<div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>IMPORTANT SAFETY INFORMATION</strong></div>
                            <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                          <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Warnings and Precautions</strong></div>
                            <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <table width='545' cellpadding='0' cellspacing='0' border='0' class='w300'>
                            	<tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Drug interactions:</strong> Use COMPLERA with caution when given with drugs that may reduce the exposure of rilpivirine or when coadministered with a drug with known risk of Torsades de Pointes. Supratherapeutic doses of rilpivirine have been shown to prolong the QTc interval of the electrocardiogram (ECG) in healthy subjects</div></td>
                                </tr>
                            </table>
                            <div style='font-size:14px; line-height:18px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Convenient Dosing</strong></div>
                             <div style='font-size:5px; line-height:8px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                       </td>
                       <td width='20' class='w10'></td>
                   </tr>
               </table></td>
            </tr>
        	<tr>
            	<td width='600' bgcolor='#e4f1fa' class='w320' align='left'><table width='600' cellpadding='0' cellspacing='0' border='0' class='w320'>
                	<tr>
                    	<td width='25' class='w10'></td>
                        <td width='555' class='w300'>
                             <table width='555' cellpadding='0' cellspacing='0' border='0' class='w300'>
                             	<tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none; mso-margin-top-alt:1px;'>
                                	<td width='8' bgcolor='#ffffff'><img src='cid:tuss14cdpr1130_box2_corner_tl.gif' width='8' height='8' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                    <td width='539' class='w284' valign='top' bgcolor='#ffffff'><table width='539' class='w284' cellpadding='0' cellspacing='0' border='0'>
                                    	<tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none;'><td width='539' class='w284' height='1' bgcolor='#75aede'><font style='display:none;'>&nbsp;</font></td></tr>
                                    </table></td>
                                    <td width='8' bgcolor='#ffffff'><img src='cid:tuss14cdpr1130_box2_corner_tr.gif' width='8' height='8' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                </tr>
                             </table>
                             <table width='555' cellpadding='0' cellspacing='0' border='0' class='w300'>
                             	<tr>
                                	<td width='1' bgcolor='#75aede'></td>
                                    <td width='16' bgcolor='#ffffff' class='w9'></td>
                                  	<td width='521' bgcolor='#ffffff' class='w280' align='center'>
                                    	<div style='font-size:5px; line-height:8px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                      	<table width='521' class='w280' cellpadding='0' cellspacing='0' border='0'>
                                        	<tr>
                                                <td width='236' class='float280' valign='top' align='center'>
                                                	<table width='202' cellpadding='0' cellspacing='0' border='0'>
                                                    	<tr>
                                                        	<td width='40' valign='middle'><img src='cid:tuss14cdpr1130_diagram4.gif' alt='DIAGRAM :: PI-based regimen(3) vs COMPLERA' width='202' height='139' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                                        </tr>
                                                    </table>
                                                    <div style='font-size:8px; line-height:10px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                                    <div align='center' style='font-family:Arial, Helvetica, sans-serif; font-size:9px; line-height:11px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>For illustrative purposes only.</div>
                                                    <div style='font-size:8px; line-height:10px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                                </td>
                                                <td width='16' class='hide'></td>
                                            	<td width='269' class='float280' valign='top' align='left'>
                                            	 	<table width='269' class='w280' cellpadding='0' cellspacing='0' border='0'>
                                                        <tr>
                                                          <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                                          <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>COMPLERA is the smallest, complete once-daily, single tablet regimen<sup>4</sup></div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                                        </tr>
                                                        <tr>
                                                          <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                                          <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>One co-pay per month</div>
                                                              <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                                        </tr>
                                                        <tr>
                                                          <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                                          <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>COMPLERA is taken with food (about 400 calories)</div>
                                                              <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                                        </tr>
                                                  	</table>
                                                    <table width='269' cellpadding='0' cellspacing='0' border='0' class='w280'>
                                                        <tr>
                                                            <td width='18'></td>
                                                            <td width='13' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>&ndash;</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                                            <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>Helps increase rilpivirine exposure</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                                        </tr>
                                                        <tr>
                                                            <td width='18'></td>
                                                            <td width='13' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>&ndash;</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                                            <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>A protein drink is not a substitute for food</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                                        </tr>
                                                    </table>
                                                    <table width='269' class='w280' cellpadding='0' cellspacing='0' border='0'>
                                                        <tr>
                                                          <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                                          <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:11px; line-height:13px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>Renal impairment: Because COMPLERA is a fixed-dose combination, it should not be prescribed for patients requiring dose adjustment, such as those with moderate or severe renal impairment (creatinine clearance below 50 mL per minute)</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                                        </tr>
                                                    </table>
                                                </td>
                                                <td width='13' class='hide'></td>
                                            </tr>
                                        </table>
                                    </td>
                                    <td width='16' bgcolor='#ffffff' class='w9'></td>
                                    <td width='1' bgcolor='#75aede'></td>
                                </tr>
                             </table>
                             <table width='555' cellpadding='0' cellspacing='0' border='0' class='w300'>
                             	<tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none; mso-margin-top-alt:1px;'>
                                	<td width='8' bgcolor='#ffffff'><img src='cid:tuss14cdpr1130_box2_corner_bl.gif' width='8' height='8' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                    <td width='539' class='w284' valign='bottom' bgcolor='#ffffff'><table width='539' class='w284' cellpadding='0' cellspacing='0' border='0'>
                                    	<tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none;'><td width='539' class='w284' height='1' bgcolor='#75aede'><font style='display:none;'>&nbsp;</font></td></tr>
                                    </table></td>
                                    <td width='8' bgcolor='#ffffff'><img src='cid:tuss14cdpr1130_box2_corner_br.gif' width='8' height='8' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /></td>
                                </tr>
                             </table>
                       </td>
                       <td width='20' class='w10'></td>
                   </tr>
               </table></td>
            </tr>
        </table></td>
    </tr>
</table>
<table width='100%' cellpadding='0' cellspacing='0' border='0'>
	<tr>
    	<td align='center'><table width='600' cellpadding='0' cellspacing='0' border='0' class='w320'>
            <tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none;'><td width='600' class='w320' height='18' bgcolor='#e4f1fa'><font style='display:none;'>&nbsp;</font></td></tr>
            <tr>
            	<td width='600' bgcolor='#e4f1fa' class='w320' align='left'><table width='600' cellpadding='0' cellspacing='0' border='0' class='w320'>
                	<tr>
                    	<td width='35' class='w10'></td>
                        <td width='545' class='w300'>
                        	<div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>IMPORTANT SAFETY INFORMATION</strong></div>
                            <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                          <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Dosage and Administration</strong></div>
                            <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Adults:</strong> One tablet taken orally once daily with food.</div>
                            <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Renal Impairment:</strong> Do not use in patients requiring dose adjustment or patients with estimated CrCl &lt;50 mL/min.</div>
                            <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <table width='545' cellpadding='0' cellspacing='0' border='0' class='w300'>
                            	<tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Drug interactions:</strong> Use COMPLERA with caution when given with drugs that may reduce the exposure of rilpivirine or when coadministered with a drug with known risk of Torsades de Pointes. Supratherapeutic doses of rilpivirine have been shown to prolong the QTc interval of the electrocardiogram (ECG) in healthy subjects</div></td>
                                </tr>
                            </table>
                            <div style='font-size:14px; line-height:18px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>IMPORTANT SAFETY INFORMATION</strong></div>
                            <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>BOXED WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B</strong></div>
                             <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                             <table width='545' cellpadding='0' cellspacing='0' border='0' class='w300'>
                            	<tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate (tenofovir DF), a component of COMPLERA, in combination with other antiretrovirals</strong></div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>COMPLERA is not approved for the treatment of chronic hepatitis B virus (HBV) infection and the safety and efficacy of COMPLERA have not been established in patients coinfected with HBV and HIV-1. Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HBV and HIV-1 and have discontinued emtricitabine or tenofovir DF, which are components of COMPLERA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue COMPLERA. If appropriate, initiation of anti-hepatitis B therapy may be warranted</strong></div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                            </table>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Contraindications</strong></div>
                             <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                             <table width='545' cellpadding='0' cellspacing='0' border='0' class='w300'>
                            	<tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Coadministration:</strong> COMPLERA should not be coadministered with drugs that induce CYP3A or increase gastric pH as this may lead to loss of virologic response and possible resistance to COMPLERA or the NNRTI class. Use of the following drugs with COMPLERA is contraindicated: carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine, proton pump inhibitors (e.g., esomeprazole, lansoprazole, dexlansoprazole, omeprazole, pantoprazole, rabeprazole), systemic dexamethasone (&gt;1 dose) and St. John&rsquo;s wort</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                            </table>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Warnings and Precautions</strong></div>
                             <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                             <table width='545' cellpadding='0' cellspacing='0' border='0' class='w300'>
                            	<tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>New onset or worsening renal impairment:</strong> Cases of acute renal failure and Fanconi syndrome have been reported with the use of tenofovir DF. In all patients, assess estimated creatinine clearance (CrCl) prior to initiating and during therapy. In patients at risk for renal dysfunction, additionally monitor serum phosphorus, urine glucose, and urine protein. Do not administer COMPLERA in patients with CrCl &lt;50 mL/min. Avoid concurrent or recent use with a nephrotoxic agent. Cases of acute renal failure, some requiring hospitalization and renal replacement therapy, have been reported after initiation of high dose or multiple NSAIDs in patients with risk factors for renal dysfunction; consider alternatives to NSAIDs in these patients. Persistent or worsening bone pain, pain in extremities, fractures and/or muscular pain or weakness may be manifestations of proximal renal tubulopathy and should prompt an evaluation of renal function</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Drug interactions:</strong> Use COMPLERA with caution when given with drugs that may reduce the exposure of rilpivirine or when coadministered with a drug with known risk of Torsades de Pointes. Supratherapeutic doses of rilpivirine have been shown to prolong the QTc interval of the electrocardiogram (ECG) in healthy subjects</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Depressive disorders:</strong> The incidence of depressive disorders (depressed mood, depression, dysphoria, major depression, mood altered, negative thoughts, suicide attempt, suicidal ideation) reported in clinical trials (N=686) was 9% (most were mild or moderate in severity); and Grades 3 and 4 depressive disorders (regardless of causality) was 1%. Suicidal ideation was reported in 4 subjects and suicide attempt was reported in 2 subjects. Patients with severe depressive symptoms should seek immediate medical evaluation and the risks of continued therapy should be determined</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Hepatotoxicity:</strong> Hepatic adverse events have been reported, including cases of hepatic toxicity in patients without pre-existing hepatic disease or other identifiable risk factors. Patients with underlying hepatitis B or C, or those with marked elevations in liver-associated tests may be at increased risk. Appropriate laboratory testing and monitoring before and during therapy is recommended in patients with underlying hepatic disease or in patients with marked elevations in liver-associated tests prior to treatment initiation; consider testing and monitoring in patients without pre-existing hepatic dysfunction or other risk factors</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Bone effects:</strong> Decreases in bone mineral density (BMD) and mineralization defects, including osteomalacia, have been seen in patients treated with tenofovir DF. Consider monitoring BMD in patients with a history of pathologic fracture or risk factors for bone loss. In patients at risk of renal dysfunction who present with persistent or worsening bone or muscle symptoms, hypophosphatemia and osteomalacia secondary to proximal renal tubulopathy should be considered</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Antiviral products:</strong> COMPLERA is a complete regimen for the treatment of HIV-1 infection. Do not coadminister with other antiretrovirals including products containing any of the same active components, products containing lamivudine, or with adefovir dipivoxil</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Fat redistribution</strong> and accumulation has been observed in patients receiving ARV therapy</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Immune reconstitution syndrome</strong>, including the occurrence of autoimmune disorders with variable times to onset, has been reported</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                            </table>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Adverse Reactions</strong></div>
                             <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                             <table width='545' cellpadding='0' cellspacing='0' border='0' class='w300'>
                            	<tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>In adults with no ARV treatment history:</strong> Common adverse reactions reported in clinical studies (incidence &ge;2%, Grades 2-4) were depressive disorders (2%), insomnia (2%) and headache (2%)</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>In virologically suppressed adults:</strong> No new types of adverse reactions to COMPLERA were identified in stable, virologically suppressed patients switching to COMPLERA from a regimen containing a protease inhibitor and ritonavir; however, the frequency of adverse reactions increased by 20% after switching to COMPLERA</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                           </table>
                           <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Drug Interactions</strong></div>
                             <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                             <table width='545' cellpadding='0' cellspacing='0' border='0' class='w300'>
                            	<tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>CYP3A inducers:</strong> Drugs that induce CYP3A may decrease rilpivirine plasma concentrations which may lead to loss of virologic response and possible resistance to COMPLERA or the NNRTI class</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>CYP3A inhibitors:</strong> Drugs that inhibit CYP3A may increase rilpivirine plasma concentrations</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Drugs increasing gastric pH</strong> may significantly decrease rilpivirine plasma concentrations and lead to loss of virologic response and possible resistance to COMPLERA or the NNRTI class</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                             </table>
                             <table width='545' cellpadding='0' cellspacing='0' border='0' class='w300'>
                            	<tr>
                                	<td width='18'></td>
                                    <td width='13' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>&ndash;</div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>Use of proton pump inhibitors with COMPLERA is contraindicated</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                	<td width='18'></td>
                                    <td width='13' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>&ndash;</div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>Antacids should be administered &ge;2 hours before or &ge;4 hours after COMPLERA</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                	<td width='18'></td>
                                    <td width='13' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>&ndash;</div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>H<sub style='vertical-align:sub; font-size:80%; line-height:0.5em;'>2</sub> receptor antagonists should be administered &ge;12 hours before or &ge;4 hours after COMPLERA</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                             </table>
                             <table width='545' cellpadding='0' cellspacing='0' border='0' class='w300'>
                            	<tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Drugs affecting renal function:</strong> Coadministration of COMPLERA with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of emtricitabine and tenofovir </div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Prescribing information:</strong> Consult the full Prescribing Information for COMPLERA for more information on potentially significant drug interactions, including clinical comments </div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                             </table>
                             <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Pregnancy and Breastfeeding</strong></div>
                             <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                             <table width='545' cellpadding='0' cellspacing='0' border='0' class='w300'>
                            	<tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Pregnancy Category B:</strong> There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if potential benefits justifies the potential risk. An Antiretroviral Pregnancy Registry has been established</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                                <tr>
                                    <td width='10' align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>&bull;</strong></div></td>
                                    <td align='left' valign='top'><div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Breastfeeding:</strong> Emtricitabine and tenofovir have been detected in human milk. Because of both the potential for HIV transmission and the potential for serious adverse reactions in nursing infants, mothers should be instructed not to breastfeed</div><div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                </tr>
                            </table>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:16px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Dosage and Administration</strong></div>
                             <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                             <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Adults:</strong> One tablet taken orally once daily with food.</div>
                             <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                             <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Renal Impairment:</strong> Do not use in patients requiring dose adjustment or patients with estimated CrCl &lt;50 mL/min.</div>
                             <div style='font-size:14px; line-height:18px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                             <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>Please see full <a href='#tbd' target='_blank' style='color:#124a89; text-decoration:underline;'>Prescribing Information</a>, including BOXED WARNING.</strong></div>
                             <div style='font-size:14px; line-height:18px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                             <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>ARV=antiretroviral; NNRTI=non-nucleoside reverse transcriptase inhibitor.</div>
                             <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                             <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:14px; line-height:18px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'><strong>References:</strong> <strong>1.</strong> COMPLERA Prescribing Information. Gilead Sciences, Inc; December 2013. <strong>2.</strong> Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. <a href='http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf' target='_blank' style='color:#124a89; text-decoration:none; cursor:text;'>http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf</a>. Accessed May 5, 2014. <strong>3.</strong> Palella FJ Jr, Fisher M, Tebas P, et al. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS. 2014;28(3):335-344. <strong>4.</strong> Data on file, Gilead Sciences, Inc.</div>
                             <div style='font-size:14px; line-height:18px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                       </td>
                       <td width='20' class='w10'></td>
                   </tr>
               </table></td>
            </tr>
            <tr>
            	<td width='600' bgcolor='#e4f1fa' class='w320' align='left'><table width='600' cellpadding='0' cellspacing='0' border='0' class='w320'>
                	<tr>
                    	<td width='25' class='w10'></td>
                        <td width='555' class='w300'>
                             <table width='555' cellpadding='0' cellspacing='0' border='0' class='w300'>
                             	<tr>
                                	<td width='121' valign='top' class='float300'><img src='cid:tuss14cdpr1130_gilead_logo.png' alt='GILEAD' width='121' border='0' style='outline:none; text-decoration:none; -ms-interpolation-mode: bicubic; display:block;' /><div style='font-size:5px; line-height:8px; -webkit-text-size-adjust:none;'>&nbsp;</div></td>
                                    <td width='8' class='hide'></td>
                                    <td width='426' valign='top' class='float300'>
                                    	<div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:12px; line-height:16px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>COMPLERA, the COMPLERA Logo, EMTRIVA, GILEAD, the GILEAD Logo,<br class='hide' /> GSI, HEPSERA, STRIBILD, TRUVADA, and VIREAD are trademarks of<br class='hide' /> Gilead Sciences, Inc., or its related companies. ATRIPLA is a trademark of<br class='hide' /> Bristol-Myers Squibb &amp; Gilead Sciences, LLC. All other marks referenced<br class='hide' /> herein are the property of their respective owners.</div>
                             			<div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                        <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:12px; line-height:16px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>&copy;2014 Gilead Sciences, Inc.  All rights reserved.  CPAP0127  5/14</div>
                                        <div style='font-size:5px; line-height:8px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                                    </td>
                                </tr>
                            </table>
                       </td>
                       <td width='20' class='w10'></td>
                   </tr>
               </table></td>
            </tr>
        </table></td>
    </tr>
</table>
<table width='100%' cellpadding='0' cellspacing='0' border='0'>
	<tr>
    	<td align='center'><table width='600' cellpadding='0' cellspacing='0' border='0' class='w320'>
            <tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none;'><td width='600' class='w320' height='12' bgcolor='#ffffff'><font style='display:none;'>&nbsp;</font></td></tr>
            <tr>
            	<td width='600' bgcolor='#ffffff' class='w320' align='left'><table width='600' cellpadding='0' cellspacing='0' border='0' class='w320'>
                	<tr>
                    	<td width='35' class='w10'></td>
                        <td width='545' class='w300'>
                        	<div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:12px; line-height:16px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404 U.S.A</div>
                            <div style='font-size:5px; line-height:6px; -webkit-text-size-adjust:none;'>&nbsp;</div>
                            <div align='left' style='font-family:Arial, Helvetica, sans-serif; font-size:12px; line-height:16px; color:#124a89; -webkit-text-size-adjust:none; -ms-text-size-adjust:100%; mso-line-height-rule:exactly; -webkit-font-smoothing:antialiased;'>This e-mail powered by Med-E-Mail connects healthcare professionals with relevant commercial messages germane to the practice of medicine. If you wish to no longer receive messages from this sender, please review your preference page <a href='#tbd' style='color:#124a89; text-decoration:underline;' target='_blank'>here</a>.</div>
                       </td>
                       <td width='20' class='w10'></td>
                   </tr>
               </table></td>
            </tr>
            <tr style='font-size:1px; line-height:0; -webkit-text-size-adjust:none;'><td width='600' class='w320' height='30' bgcolor='#ffffff'><font style='display:none;'>&nbsp;</font></td></tr>
        </table></td>
    </tr>
</table>
</body>
</html>
